X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (29268) 29268
Publication (2270) 2270
Book Review (435) 435
Newsletter (377) 377
Book Chapter (93) 93
Newspaper Article (51) 51
Conference Proceeding (31) 31
Magazine Article (31) 31
Book / eBook (11) 11
Dissertation (5) 5
Data Set (3) 3
Trade Publication Article (3) 3
Reference (2) 2
Paper (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (21031) 21031
male (10877) 10877
animals (9689) 9689
female (9588) 9588
index medicus (9352) 9352
middle aged (6419) 6419
aged (5345) 5345
adult (4207) 4207
peripheral vascular disease (4120) 4120
tissue plasminogen activator - therapeutic use (4027) 4027
plasminogen-activator (3939) 3939
thrombolytic therapy (3685) 3685
stroke (3526) 3526
tissue plasminogen activator (3421) 3421
fibrinolytic agents - therapeutic use (3305) 3305
treatment outcome (3282) 3282
mice (3220) 3220
thrombolysis (3218) 3218
hematology (3162) 3162
time factors (2953) 2953
tissue-plasminogen activator (2819) 2819
rats (2761) 2761
fibrinolysis (2604) 2604
stroke - drug therapy (2509) 2509
clinical neurology (2485) 2485
cells, cultured (2441) 2441
tissue plasminogen activator - administration & dosage (2411) 2411
fibrinolysis - drug effects (2375) 2375
cardiac & cardiovascular systems (2161) 2161
expression (2121) 2121
biochemistry & molecular biology (2120) 2120
neurosciences (2110) 2110
risk factors (2080) 2080
myocardial infarction - drug therapy (2067) 2067
therapy (1927) 1927
aged, 80 and over (1914) 1914
fibrinolytic agents - administration & dosage (1896) 1896
dose-response relationship, drug (1857) 1857
pharmacology & pharmacy (1847) 1847
urokinase (1799) 1799
analysis (1759) 1759
tissue plasminogen activator - adverse effects (1725) 1725
oncology (1704) 1704
thrombolytic therapy - methods (1677) 1677
research (1645) 1645
care and treatment (1628) 1628
plasminogen-activator inhibitor-1 (1602) 1602
acute ischemic-stroke (1583) 1583
thrombosis (1559) 1559
cell biology (1529) 1529
ischemia (1515) 1515
disease models, animal (1485) 1485
surgery (1455) 1455
plasminogen activator inhibitor 1 - metabolism (1443) 1443
fibrinolytic agents - adverse effects (1408) 1408
brain ischemia - drug therapy (1383) 1383
urokinase-type plasminogen activator - metabolism (1379) 1379
health aspects (1367) 1367
tissue-plasminogen-activator (1347) 1347
urokinase-type plasminogen activator - therapeutic use (1346) 1346
acute myocardial-infarction (1323) 1323
thrombolytic therapy - adverse effects (1299) 1299
plasminogen activator inhibitor 1 - genetics (1237) 1237
retrospective studies (1212) 1212
prospective studies (1193) 1193
thrombolytic drugs (1177) 1177
mortality (1175) 1175
drug therapy (1165) 1165
article (1162) 1162
inflammation (1160) 1160
cancer (1140) 1140
plasminogen (1126) 1126
proteins (1117) 1117
neurology (1110) 1110
thrombosis - drug therapy (1105) 1105
tissue plasminogen activator - metabolism (1097) 1097
medicine & public health (1077) 1077
alteplase (1054) 1054
recombinant proteins - therapeutic use (1029) 1029
tissue plasminogen activator - pharmacology (1028) 1028
plasminogen - metabolism (1027) 1027
streptokinase - therapeutic use (1006) 1006
acute disease (1002) 1002
cell line (997) 997
medicine, general & internal (994) 994
endothelial-cells (986) 986
blood coagulation - drug effects (973) 973
trial (958) 958
prognosis (957) 957
rabbits (948) 948
drug therapy, combination (940) 940
in-vitro (939) 939
plasminogen activator inhibitor 1 - blood (935) 935
endothelium, vascular - drug effects (925) 925
endocrinology & metabolism (922) 922
physiological aspects (920) 920
urokinase-type plasminogen activator - administration & dosage (912) 912
fibrin (905) 905
myocardial-infarction (904) 904
fibrinolytic agents - pharmacology (902) 902
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28528) 28528
German (341) 341
Chinese (207) 207
Russian (167) 167
Japanese (161) 161
French (149) 149
Spanish (62) 62
Italian (59) 59
Polish (42) 42
Danish (12) 12
Hungarian (11) 11
Ukrainian (11) 11
Dutch (9) 9
Portuguese (8) 8
Norwegian (7) 7
Czech (6) 6
Swedish (4) 4
Romanian (2) 2
Serbian (2) 2
Bulgarian (1) 1
Finnish (1) 1
Hebrew (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Nephrology, ISSN 1759-5061, 05/2010, Volume 6, Issue 5, pp. 261 - 273
Journal Article
Journal Article
Journal of Ethnopharmacology, ISSN 0378-8741, 10/2011, Volume 138, Issue 1, pp. 22 - 33
Bu-yang Huan-wu decoction (BHD) is a famous traditional Chinese medicine formula that has been used clinically in Asia to treat stroke-induced disability for... 
Cerebral ischemia–reperfusion (CI/R) | Oxidative stress | Positron emission tomography (PET) | Bu-yang Huan-wu decoction | Inflammation | Microarray | Neurogenesis | Neurological deficits | Genome-wide transcriptome analysis | Infarction | Mice | Functional modules and genetic networks | Apoptosis | Cerebral ischemia-reperfusion (CI/R) | ACTIVATION | BRAIN-INJURY | NEURONAL INJURY | RATS | KAPPA-B | INFARCT VOLUME | PHARMACOLOGY & PHARMACY | CHEMISTRY, MEDICINAL | FOCAL CEREBRAL-ISCHEMIA | PLANT SCIENCES | INTEGRATIVE & COMPLEMENTARY MEDICINE | ACCUMULATION | Neuroprotective Agents - therapeutic use | Neovascularization, Physiologic - drug effects | Gene Expression - drug effects | Apoptosis - drug effects | Brain Ischemia - genetics | Drugs, Chinese Herbal - pharmacology | Apoptosis - genetics | Male | Brain - physiology | Cerebral Infarction - prevention & control | Stroke - genetics | Neurogenesis - genetics | Neuroprotective Agents - pharmacology | Inflammation - drug therapy | Anti-Inflammatory Agents - therapeutic use | Neurogenesis - drug effects | Phytotherapy | Stroke - mortality | Drugs, Chinese Herbal - therapeutic use | Anti-Inflammatory Agents - pharmacology | Neovascularization, Physiologic - genetics | Oxidative Stress - genetics | Astragalus Plant | Stroke - drug therapy | Antioxidants - pharmacology | Brain Ischemia - etiology | Mice, Inbred ICR | Brain - drug effects | Antioxidants - therapeutic use | Animals | Tissue Plasminogen Activator - pharmacology | Blood Coagulation - drug effects | Brain Ischemia - drug therapy | Inflammation - genetics | Blood Coagulation - genetics | Oxidative Stress - drug effects | Medicine, Chinese | Sports sciences | Ischemia | Analysis | Genomics | Blood coagulation | Brain | Cerebral infarction | Neuroprotection | Stroke | Nervous system | Gene expression | Neurological diseases | plasminogen | Angiogenesis | MK-801 | Life span | genomics | Injuries
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 06/2017, Volume 19, Issue 6, pp. 901 - 905
We assessed the effects of liraglutide treatment on five cardiovascular risk biomarkers, reflecting different pathophysiology: tumour necrosis factor (TNF)‐α;... 
clinical trial | liraglutide | GLP‐1 analogue | GLP-1 analogue | ATHEROSCLEROSIS | MECHANISMS | BLOOD-PRESSURE | ALL-CAUSE MORTALITY | NATRIURETIC-PEPTIDE | MIDREGIONAL FRAGMENT | GLUCAGON-LIKE PEPTIDE-1 | MICROALBUMINURIA | INFLAMMATION | ENDOCRINOLOGY & METABOLISM | CALCIFICATION | Protein Precursors - blood | Albuminuria - blood | Humans | Middle Aged | Tumor Necrosis Factor-alpha - blood | Atrial Natriuretic Factor - drug effects | Male | Receptors, Urokinase Plasminogen Activator - blood | Receptors, Urokinase Plasminogen Activator - drug effects | Atrial Natriuretic Factor - blood | Peptide Fragments - blood | Adrenomedullin - drug effects | Female | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Albuminuria - etiology | Double-Blind Method | Glycopeptides - drug effects | Risk Factors | Adrenomedullin - blood | Biomarkers - blood | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Protein Precursors - drug effects | Tumor Necrosis Factor-alpha - drug effects | Albuminuria - drug therapy | Liraglutide - therapeutic use | Peptide Fragments - drug effects | Glycopeptides - blood | Aged | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Care and treatment | Cardiac patients | Clinical trials | Cardiovascular diseases | Biological markers | Risk factors | Natriuretic peptides | Diabetes therapy | Biomarkers | Tumor necrosis factor-TNF | Diabetes
Journal Article
Journal of Biological Chemistry, ISSN 0021-9258, 07/2016, Volume 291, Issue 29, pp. 15029 - 15045
Urokinase-type plasminogen activator (uPA) regulates angiogenesis and vascular permeability through proteolytic degradation of extracellular matrix and... 
SIGNAL-TRANSDUCTION | CELL-MIGRATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | KRINGLE DOMAIN | NUCLEOLIN | SURFACE | SINGLE-CHAIN PROUROKINASE | EXTRACELLULAR-MATRIX | STROMAL CELLS | BINDING | CORONARY-ARTERY-DISEASE | Neovascularization, Physiologic - drug effects | Homeodomain Proteins - metabolism | Humans | RNA, Messenger - metabolism | Promoter Regions, Genetic - genetics | Vascular Endothelial Growth Factor Receptor-2 - genetics | Cell Nucleus - metabolism | Protein Binding - drug effects | HEK293 Cells | Vascular Endothelial Growth Factor A - pharmacology | Vascular Endothelial Growth Factor Receptor-1 - genetics | Endothelial Cells - metabolism | RNA, Messenger - genetics | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Mice, Knockout | Transcription Factors - metabolism | Cell Movement - drug effects | Animals | Signal Transduction - drug effects | Urokinase-Type Plasminogen Activator - metabolism | Endothelial Cells - cytology | K562 Cells | Cell Proliferation - drug effects | Cell Nucleus - drug effects | Endothelial Cells - drug effects | nuclear translocation | angiogenesis | endothelial cell | VEGF Receptors | PRH | urokinase plasminogen activator | vascular endothelial growth factor (VEGF) | vascular biology | HHEX transcription factor | Cell Biology
Journal Article
Journal Article
Journal of Pharmacology and Experimental Therapeutics, ISSN 0022-3565, 03/2013, Volume 344, Issue 3, pp. 600 - 615
5'-Benzylglycinyl-amiloride (UCD38B) and glycinyl-amiloride (UCD74A) are cell-permeant and cell-impermeant derivatives of amiloride, respectively, and used... 
THERAPY | HIF-2-ALPHA | PLASMINOGEN-ACTIVATOR | EXCHANGE INHIBITION | GROWTH | PROGRAMMED NECROSIS | AMILORIDE | PHARMACOLOGY & PHARMACY | HISTONE H2AX | DEATH | FACTOR AIF | Cell Cycle - genetics | Cyclin D1 - metabolism | RNA, Small Interfering - genetics | Apoptosis - drug effects | Humans | Amiloride - analogs & derivatives | Endoplasmic Reticulum - metabolism | Apoptosis - genetics | Protein Transport - drug effects | Membrane Potential, Mitochondrial - drug effects | Autophagy - drug effects | Glioma - metabolism | Sodium-Hydrogen Exchangers - metabolism | Glioma - genetics | Caspases - metabolism | Cell Nucleus - metabolism | Cell Death - genetics | Mitochondria - genetics | Endoplasmic Reticulum - drug effects | Glioma - pathology | Membrane Potential, Mitochondrial - genetics | Cell Cycle Checkpoints - genetics | Sodium-Hydrogen Exchangers - genetics | Autophagy - genetics | Cell Death - drug effects | Apoptosis Inducing Factor - metabolism | Caspases - genetics | Mitochondria - metabolism | Urokinase-Type Plasminogen Activator - genetics | Protein Transport - genetics | Apoptosis Inducing Factor - genetics | Poly(ADP-ribose) Polymerases - metabolism | Histones - genetics | Poly(ADP-ribose) Polymerases - genetics | Cell Nucleus - genetics | Cyclin D1 - genetics | Urokinase-Type Plasminogen Activator - metabolism | Cell Cycle Checkpoints - drug effects | Amiloride - pharmacology | Cell Line, Tumor | Cell Proliferation - drug effects | Histones - metabolism | Poly (ADP-Ribose) Polymerase-1 | Cell Cycle - drug effects | Glioma - drug therapy
Journal Article